Skip to main content
Top
Published in: Irish Journal of Medical Science (1971 -) 6/2023

16-03-2023 | Obesity | Original Article

The triglycerides and glucose index is highly associated with non-alcoholic fatty liver disease in overweight and obese women

Authors: Heriberto Rodríguez-Hernández, Luis E. Simental-Mendía

Published in: Irish Journal of Medical Science (1971 -) | Issue 6/2023

Login to get access

Abstract

Background

Although some previous studies have indicated that the triglycerides and glucose (TyG) index is associated with an increased risk of non-alcoholic fatty liver disease (NAFLD), there are still few studies in this field.

Aims

The goal of this study was to assess whether the TyG index is associated with the presence of non-alcoholic fatty liver disease NAFLD in overweight and obese women.

Methods

Overweight and obese women aged 20 to 65 years were enrolled in a cross-sectional study and allocated into the groups with and without NAFLD. Alcohol consumption, pregnancy, normal-weight, positive markers of viral or autoimmune hepatitis, acute or chronic liver disease, renal disease, cardiovascular disease, neoplasia, and intake of hepatotoxic drugs were exclusion criteria. The diagnosis of NAFLD was established by liver ultrasound and the TyG index was calculated as the Ln [fasting triglycerides (mg/dL) × fasting glucose (mg/dL)]/2.

Results

A total of 420 participants were enrolled and allocated into the groups with (n = 212) and without (n = 208) NAFLD. In the overall population, the frequency of NAFLD was 50.4%. The logistic regression analysis adjusted by body mass index, waist circumference, and total body fat showed that total cholesterol (OR = 1.004; 95% CI: 1.000–1.007), triglycerides (OR = 1.002; 95% CI: 1.000–1.004), AST (OR = 1.19; 95% CI: 1.15–1.23), ALT (OR = 1.20; 95% CI: 1.15–1.25), and TyG index (OR = 3.15; 95% CI: 1.64–6.06) are significantly associated with NAFLD.

Conclusions

The results show that the TyG index is highly associated with the presence of NAFLD in women with overweight and obesity.
Literature
8.
go back to reference Khamseh ME, Malek M, Abbasi R et al (2021) Triglyceride glucose index and related parameters (triglyceride glucose-body mass index and triglyceride glucose-waist circumference) identify nonalcoholic fatty liver and liver fibrosis in individuals with overweight/obesity. Metab Syndr Relat Disord 19:167–173. https://doi.org/10.1089/met.2020.0109CrossRefPubMed Khamseh ME, Malek M, Abbasi R et al (2021) Triglyceride glucose index and related parameters (triglyceride glucose-body mass index and triglyceride glucose-waist circumference) identify nonalcoholic fatty liver and liver fibrosis in individuals with overweight/obesity. Metab Syndr Relat Disord 19:167–173. https://​doi.​org/​10.​1089/​met.​2020.​0109CrossRefPubMed
10.
go back to reference Wang X, Zhou W, Song Q, Xie Y (2023) Association of the triglyceride-glucose index with the occurrence of non-alcoholic fatty liver disease and mortality in elderly inpatients: a prospective observational study. Nutr Hosp. https://doi.org/10.20960/NH.04435 Wang X, Zhou W, Song Q, Xie Y (2023) Association of the triglyceride-glucose index with the occurrence of non-alcoholic fatty liver disease and mortality in elderly inpatients: a prospective observational study. Nutr Hosp. https://​doi.​org/​10.​20960/​NH.​04435
15.
26.
go back to reference Gastaldelli A, Folli FDR (2010) The product of triglycerides and glucose as index of insulin resistance. Validation in the SAM study. J Clin Endocrinol Metab 95:3351 Gastaldelli A, Folli FDR (2010) The product of triglycerides and glucose as index of insulin resistance. Validation in the SAM study. J Clin Endocrinol Metab 95:3351
Metadata
Title
The triglycerides and glucose index is highly associated with non-alcoholic fatty liver disease in overweight and obese women
Authors
Heriberto Rodríguez-Hernández
Luis E. Simental-Mendía
Publication date
16-03-2023
Publisher
Springer International Publishing
Published in
Irish Journal of Medical Science (1971 -) / Issue 6/2023
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-023-03335-4

Other articles of this Issue 6/2023

Irish Journal of Medical Science (1971 -) 6/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine